Posted by Michael Wonder on 01 Feb 2024
ICER publishes evidence report on treatments for paroxysmal nocturnal haemoglobinuria
1 February 2024 - Iptacopan and danicopan are two first in class agents that provide important health benefits, but there are uncertainties regarding long-term efficacy and safety.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of iptacopan (Novartis) and danicopan (Alexion Pharmaceuticals) for the treatment of paroxysmal nocturnal haemoglobinuria.
